|  |  | Time to progression |  |  |  | Overall survival |  |  |
---|---|---|---|---|---|---|---|---|---|
Risk factor | n | HR | 95% CI | Â | P | HR | 95% CI | Â | P |
Regimen (GD vs. D) | Â | 0.60 | (0.42- | 0.84) | 0.003 | 0.88 | (0.67- | 1.15) | 0.34 |
TIMP-1 (positive vs. negative) | Â | 0.82 | (0.55- | 1.21) | 0.31 | 0.71 | (0.52- | 0.98) | 0.03 |
PAM50 | Â | Â | Â | Â | 0.007 | Â | Â | Â | 0.0001 |
  Luminal A | 78 | 0.68 | (0.45- | 1.04) | 0.08 | 0.78 | 0.56 | 1.08 | 0.14 |
  Luminal B | 100b | 1.00 | referent |  |  | 1.00 | referent |  |  |
  Basal-like | 40 | 1.75 | (1.05- | 2.92) | 0.03 | 2.39 | (1.56- | 3.64) | <0.0001 |
  HER2-enriched | 46 | 1.30 | (0.82- | 2.07) | 0.27 | 1.25 | (0.85- | 1.84) | 0.25 |
Visceral disease (yes vs. no) | Â | 1.60 | (1.07- | 2.39) | 0.02 | 1.13 | (0.84- | 1.53) | 0.42 |
Stage of disease (locally advanced vs. metastatic) | 1.96 | (1.02- | 3.76) | 0.04 | 0.72 | (0.42- | 1.24) | 0.23 | |
Metastatic sites (3+ vs. 1-2) | Â | 1.24 | (0.86- | 1.77) | 0.25 | 1.52 | (1.13- | 2.04) | 0.01 |
ECOG performance status (2 vs. 0-1) | Â | 1.19 | (0.85- | 1.67) | 0.31 | 1.47 | (1.12- | 1.93) | 0.006 |